Mojgan Allahyari - Recombinant Protein Production Department, Production and Research Complex, Pasteur Institute of Iran, Karaj, Iran.
Samira amiri - Molecular Parasitology Laboratory, Department of Parasitology, Pasteur Institute of Iran, Tehran, Iran
Alireza Vatanara - Department of Pharmaceutics, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Majid Golkar - Molecular Parasitology Laboratory, Department of Parasitology, Pasteur Institute of Iran, Tehran, Iran.

Introduction: This study aimed to evaluate rSAG۱-PLGA efficacy as a particulate vaccine in conferring protection against Toxoplasma gondii infection in C۵۷BL/۶ mice. In light of our previous studies, we studied mice genotype role in eliciting immune responses by rSAG۱-PLGA nanoparticles in this study. Methods: Poly (DL-lactide-co-glycolide) (PLGA) nanoparticles loaded by rSAG۱ as a subunit vaccine were prepared, and C۵۷BL/۶ mice were subcutaneously immunized twice at a ۳-week interval by rSAG۱-PLGA, soluble rSAG۱, blank PLGA, and one group kept unvaccinated. The characteristics of PLGA nanoparticles, the amounts of produced IFN-γ, IL-۱۰, specific anti-ToxoplasmaIgGs, and the conferred protection against infection by T. gondii RH tachyzoite were assessed. Results: rSAG۱-PLGA nanoparticles shared a z-average of about ۴۵۰nm with negative Zeta potential. Compared with the negative control group, the mice vaccinated with rSAG۱-PLGA nanoparticles produced significantly higher amounts of IFN-γ, specific anti-T. gondii IgG antibodies and higher titer of IgG۲a, which resulted in longer survival times. Conclusion: The efficiency of rSAG۱-PLGA nanoparticles in inducing humoral and cellular responses and consequently partial protection against acute toxoplasmosis in C۵۷BL/۶ was confirmed.

: rSAG۱-PLGA, Toxoplasma gondii, vaccine, C۵۷BL/۶, nanoparticles